EmailExperimental AAV-Tyrosinase Based Anti-Melanoma Vaccine
Study Objective
The purpose of this study is to evaluate the safety and preliminary efficacy of a novel vaccine in companion dogs diagnosed with oral melanoma. A tumor-specific antigen (tyrosinase) carried by a FDA-approved bioengineered viral vector (AdenoAssociated Virus; AAV) is injected intramuscularly into the quadriceps muscle of the rear leg. Dogs will be vaccinated once with the AAV-Tyrosinase vaccine in a 3 x 3 dose escalation trial.
